Efficacy and tolerability of first-line triple therapy with levofloxacin and amoxicillin plus esomeprazole or rabeprazole for the eradication of Helicobacter pylori infection and the effect of CYP2C19 genotype: a 1-week, randomized, open-label study (Q42789749)
Jump to navigation
Jump to search
scientific article published on November 2010
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Efficacy and tolerability of first-line triple therapy with levofloxacin and amoxicillin plus esomeprazole or rabeprazole for the eradication of Helicobacter pylori infection and the effect of CYP2C19 genotype: a 1-week, randomized, open-label study |
scientific article published on November 2010 |
Statements
1 reference
Efficacy and tolerability of first-line triple therapy with levofloxacin and amoxicillin plus esomeprazole or rabeprazole for the eradication of Helicobacter pylori infection and the effect of CYP2C19 genotype: a 1-week, randomized, open-label study (English)
1 reference
Xiaolin Pan
1 reference
Yuqing Li
1 reference
Yuping Qiu
1 reference
Qiyun Tang
1 reference
Bingbing Qian
1 reference
Linhua Yao
1 reference
Ruihua Shi
1 reference
Guoxin Zhang
1 reference
1 November 2010
1 reference
1 reference
Identifiers
1 reference